Skip to main content
Premium Trial:

Request an Annual Quote

Oxford BioDynamics Fiscal 2019 Revenues Down 24 Percent

NEW YORK — Oxford BioDynamics reported on Wednesday a 24 percent drop in revenues for its fiscal year 2019 amid a decline in revenues generated in the US.

For the 12-month period ended Sept. 30, the UK-based company's revenues — which were generated entirely from epigenetic biomarker research and development alliances with commercial and academic partners — fell to £907,000 ($1.2 million) from £1.2 million in the same period last year. US revenues were down 69 percent to £126,000 from £405,000, while revenues generated in the rest of the world were flat at £781,000.

"Not only have we signed additional collaboration agreements [in 2019], but we have also seen EpiSwitch [biomarker technology] being used in high profile UK and US clinical trials," Oxford BioDynamics CEO Christian Hoyer Millar said in a statement. "We believe there is significant potential for EpiSwitch biomarkers to benefit a range of diseases, but we have been particularly pleased with the progress we have announced in [immuno-oncology.]"

Earlier this year, Oxford BioDynamics announced that its EpiSwitch test for prostate cancer will be evaluated in a nearly 300-patient study in the UK.

Oxford BioDynamics' fiscal 2019 net loss grew to £2.8 million, or £.03 per share, from £2.0 million, or £.02 per share, the year before.

R&D spending declined 32 percent to £468,000 from £693,000, while general and administrative costs grew 27 percent to £1.4 million from £1.1 million.

At the end of September, Oxford BioDynamics had cash and cash equivalents totaling £5.2 million.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.